145 related articles for article (PubMed ID: 38687076)
21. Activity of cefiderocol and synergy of novel β-lactam-β-lactamase inhibitor-based combinations against metallo-β-lactamase-producing gram-negative bacilli: insights from a two-year study (2019-2020).
Boattini M; Comini S; Bianco G; Iannaccone M; Casale R; Cavallo R; Costa C
J Chemother; 2023 May; 35(3):198-204. PubMed ID: 35731718
[TBL] [Abstract][Full Text] [Related]
22. Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae.
Haidar G; Clancy CJ; Chen L; Samanta P; Shields RK; Kreiswirth BN; Nguyen MH
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630202
[TBL] [Abstract][Full Text] [Related]
23. Assessing the in vivo impact of novel β-lactamase inhibitors on the efficacy of their partner β-lactams against serine carbapenemase-producing Pseudomonas aeruginosa using human-simulated exposures.
Ruiz VH; Gill CM; Nicolau DP
J Antimicrob Chemother; 2024 Mar; 79(3):546-551. PubMed ID: 38217443
[TBL] [Abstract][Full Text] [Related]
24. Relebactam Is a Potent Inhibitor of the KPC-2 β-Lactamase and Restores Imipenem Susceptibility in KPC-Producing Enterobacteriaceae.
Papp-Wallace KM; Barnes MD; Alsop J; Taracila MA; Bethel CR; Becka SA; van Duin D; Kreiswirth BN; Kaye KS; Bonomo RA
Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29610205
[TBL] [Abstract][Full Text] [Related]
25. Activity of Imipenem-Relebactam and Meropenem-Vaborbactam against Carbapenem-Resistant, SME-Producing Serratia marcescens.
Biagi M; Shajee A; Vialichka A; Jurkovic M; Tan X; Wenzler E
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31932381
[TBL] [Abstract][Full Text] [Related]
26. Review of Ceftazidime-Avibactam, Meropenem-Vaborbactam, and Imipenem/Cilastatin-Relebactam to Target
Hayden DA; White BP; Bennett KK
J Pharm Technol; 2020 Oct; 36(5):202-210. PubMed ID: 34752560
[No Abstract] [Full Text] [Related]
27. Genomic characterization of a KPC-23-producing Klebsiella pneumoniae ST258 clinical isolate resistant to ceftazidime-avibactam.
Galani I; Antoniadou A; Karaiskos I; Kontopoulou K; Giamarellou H; Souli M
Clin Microbiol Infect; 2019 Jun; 25(6):763.e5-763.e8. PubMed ID: 30928562
[TBL] [Abstract][Full Text] [Related]
28.
Findlay J; Rens C; Poirel L; Nordmann P
Antimicrob Agents Chemother; 2022 Oct; 66(10):e0091822. PubMed ID: 36154170
[TBL] [Abstract][Full Text] [Related]
29. Activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against isogenic strains of Escherichia coli expressing single and double β-lactamases under high and low permeability conditions.
Blanco-Martín T; Alonso-García I; González-Pinto L; Outeda-García M; Guijarro-Sánchez P; López-Hernández I; Pérez-Vázquez M; Aracil B; López-Cerero L; Fraile-Ribot P; Oliver A; Vázquez-Ucha JC; Beceiro A; Bou G; Arca-Suárez J;
Int J Antimicrob Agents; 2024 May; 63(5):107150. PubMed ID: 38513748
[TBL] [Abstract][Full Text] [Related]
30. Impact of
Rogers TM; Kline EG; Griffith MP; Jones CE; Rubio AM; Squires KM; Shields RK
JAC Antimicrob Resist; 2023 Apr; 5(2):dlad022. PubMed ID: 36968951
[TBL] [Abstract][Full Text] [Related]
31. In vitro activity of imipenem/relebactam, meropenem/vaborbactam, ceftazidime/avibactam, cefepime/zidebactam and other novel antibiotics against imipenem-non-susceptible Gram-negative bacilli from Taiwan.
Kuo SC; Wang YC; Tan MC; Huang WC; Shiau YR; Wang HY; Lai JF; Huang IW; Lauderdale TL
J Antimicrob Chemother; 2021 Jul; 76(8):2071-2078. PubMed ID: 33956969
[TBL] [Abstract][Full Text] [Related]
32. In vitro activity of cefiderocol against ceftazidime-avibactam susceptible and resistant KPC-producing Enterobacterales: cross-resistance and synergistic effects.
Bianco G; Boattini M; Comini S; Iannaccone M; Bondi A; Cavallo R; Costa C
Eur J Clin Microbiol Infect Dis; 2022 Jan; 41(1):63-70. PubMed ID: 34462816
[TBL] [Abstract][Full Text] [Related]
33. A Ceftazidime-Avibactam-Resistant and Carbapenem-Susceptible Klebsiella pneumoniae Strain Harboring
Niu S; Chavda KD; Wei J; Zou C; Marshall SH; Dhawan P; Wang D; Bonomo RA; Kreiswirth BN; Chen L
mSphere; 2020 Aug; 5(4):. PubMed ID: 32848008
[TBL] [Abstract][Full Text] [Related]
34. Molecular Basis of Class A β-Lactamase Inhibition by Relebactam.
Tooke CL; Hinchliffe P; Lang PA; Mulholland AJ; Brem J; Schofield CJ; Spencer J
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31383664
[TBL] [Abstract][Full Text] [Related]
35. Multidrug-resistant Gram-negative clinical isolates with reduced susceptibility/resistance to cefiderocol: which are the best present and future therapeutic alternatives?
Le Terrier C; Freire S; Nordmann P; Poirel L
Eur J Clin Microbiol Infect Dis; 2024 Feb; 43(2):339-354. PubMed ID: 38095831
[TBL] [Abstract][Full Text] [Related]
36. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing
Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F
Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755
[TBL] [Abstract][Full Text] [Related]
37. Ceftazidime-avibactam, meropenen-vaborbactam, and imipenem-relebactam in combination with aztreonam against multidrug-resistant, metallo-β-lactamase-producing Klebsiella pneumoniae.
Maraki S; Mavromanolaki VE; Moraitis P; Stafylaki D; Kasimati A; Magkafouraki E; Scoulica E
Eur J Clin Microbiol Infect Dis; 2021 Aug; 40(8):1755-1759. PubMed ID: 33595756
[TBL] [Abstract][Full Text] [Related]
38. Comparative Activities of Novel Therapeutic Agents against Molecularly Characterized Clinical Carbapenem-Resistant
Teo JQ; Chang HY; Tan SH; Tang CY; Ong RT; Ko KKK; Chung SJ; Tan TT; Kwa AL
Microbiol Spectr; 2023 Jun; 11(3):e0100223. PubMed ID: 37184408
[TBL] [Abstract][Full Text] [Related]
39. In vitro activity of imipenem/relebactam, meropenem/vaborbactam and comparators against Enterobacterales causing urinary tract infection in Taiwan: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2020.
Chang CY; Lee YL; Huang YT; Ko WC; Ho MW; Hsueh PR
Int J Antimicrob Agents; 2023 Jun; 61(6):106815. PubMed ID: 37059343
[TBL] [Abstract][Full Text] [Related]
40. Potency of Vaborbactam Is Less Affected than That of Avibactam in Strains Producing KPC-2 Mutations That Confer Resistance to Ceftazidime-Avibactam.
Tsivkovski R; Lomovskaya O
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]